Wall Street brokerages forecast that West Pharmaceutical Services, Inc. (NYSE:WST) will report sales of $665.55 million for the current quarter, according to Zacks. Three analysts have provided estimates for West Pharmaceutical Services’ earnings, with estimates ranging from $660.10 million to $671.55 million. West Pharmaceutical Services reported sales of $527.20 million during the same quarter last year, which indicates a positive year-over-year growth rate of 26.2%. The firm is expected to report its next quarterly earnings results before the market opens on Thursday, July 29th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $2.66 billion for the current year, with estimates ranging from $2.64 billion to $2.68 billion. For the next financial year, analysts anticipate that the company will post sales of $2.89 billion, with estimates ranging from $2.84 billion to $2.92 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, April 29th. The medical instruments supplier reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.63. West Pharmaceutical Services had a return on equity of 25.08% and a net margin of 18.19%. The firm had revenue of $670.70 million for the quarter, compared to analyst estimates of $614.77 million.
Shares of NYSE WST traded up $6.02 during trading on Friday, reaching $373.97. The company had a trading volume of 8,588 shares, compared to its average volume of 340,820. The company has a fifty day simple moving average of $351.83. West Pharmaceutical Services has a 12 month low of $252.80 and a 12 month high of $377.19. The company has a market cap of $27.61 billion, a PE ratio of 64.37, a P/E/G ratio of 2.02 and a beta of 0.99. The company has a current ratio of 2.75, a quick ratio of 2.11 and a debt-to-equity ratio of 0.14.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 4th. Investors of record on Wednesday, July 21st will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 0.18%. The ex-dividend date is Tuesday, July 20th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 14.29%.
In related news, insider Silji Abraham sold 2,171 shares of the company’s stock in a transaction that occurred on Monday, May 10th. The stock was sold at an average price of $335.00, for a total transaction of $727,285.00. Following the transaction, the insider now directly owns 6,077 shares of the company’s stock, valued at approximately $2,035,795. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.66% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the company. Vantage Consulting Group Inc purchased a new stake in shares of West Pharmaceutical Services in the fourth quarter worth approximately $26,000. Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter worth approximately $28,000. Regent Peak Wealth Advisors LLC purchased a new stake in shares of West Pharmaceutical Services in the fourth quarter worth approximately $31,000. Eudaimonia Partners LLC purchased a new stake in shares of West Pharmaceutical Services in the first quarter worth approximately $31,000. Finally, Sowell Financial Services LLC raised its stake in shares of West Pharmaceutical Services by 94.8% in the first quarter. Sowell Financial Services LLC now owns 113 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 55 shares during the last quarter. 91.92% of the stock is owned by hedge funds and other institutional investors.
About West Pharmaceutical Services
West Pharmaceutical Services, Inc designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components.
Featured Article: What does a dividend yield signify to investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.